⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18723291 | 0.90 | — | — | |
| SCHEMBL21788087 | 0.88 | — | — | |
| SCHEMBL21558321 | 0.88 | — | — | |
| SCHEMBL24174346 | 0.88 | PSMB8 (0.30) | — | |
| SCHEMBL14712371 | 0.88 | PSMB8 (0.30) | — | |
| SCHEMBL18613075 | 0.87 | — | — | |
| SCHEMBL21706336 | 0.86 | — | — | |
| SCHEMBL19646887 | 0.85 | — | — | |
| SCHEMBL13257111 | 0.85 | PSMB8 (0.32) | — | |
| SCHEMBL19189415 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409612-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LTD (GB) | 2022-12-29 | — | — | US | disclosed |
| WO-2021178890-A1 | INNATE IMMUNITY KILLER CELLS TARGETING PSMA POSITIVE TUMOR CELLS | SORRENTO THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| EP-3351248-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3824909-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3423105-B1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-2555777-B1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3351248-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017177055-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | ZHAO LIANG (US) | 2017-10-12 | — | — | WO | disclosed |